The drug produces an unmistakable altered state. You know when you have taken it.
In a Stockholm clinical trial, a single dose of psilocybin offered people living with recurring depression a window of relief that opened quickly and held for months — a finding that adds weight to a growing body of evidence, while also deepening one of medicine's oldest puzzles: how much of healing belongs to the remedy, and how much to the hope that surrounds it.
- Participants who received psilocybin began reporting mood shifts within eight days — a speed that conventional antidepressants rarely match.
- More than half of the psilocybin group no longer met clinical criteria for depression at six weeks, compared to just one person in the placebo group.
- The gains began narrowing after three months, and by four months both groups were converging — with roughly a third of each starting standard antidepressants.
- Nearly every participant could tell whether they had received the drug or the placebo, undermining the trial's blinding and raising the possibility that expectation, not chemistry alone, drove some of the benefit.
- Two participants experienced anxiety lasting several weeks, a reminder that even promising treatments carry real costs for real people.
Thirty-five people with recurring depression enrolled in a Karolinska Institutet trial, receiving either a single dose of psilocybin or a vitamin B3 placebo designed to mimic some of the drug's physical sensations. Everyone received psychological support throughout. The researchers wanted to know whether psilocybin could help people with ordinary depression — not just those for whom every other treatment had failed.
The early results were striking. Within eight days, psilocybin recipients reported meaningful mood improvements. By week six, more than half no longer met the clinical definition of depression. In the placebo group, only one person reached that threshold. The drug was generally well tolerated, though two participants experienced anxiety that lingered for several weeks.
Over the following months, the picture grew more complicated. The psilocybin group's benefits held for just over three months before beginning to fade. The placebo group, following its own quiet rhythm, gradually improved as well — a pattern consistent with how depression naturally moves in waves. Around the four-month mark, roughly a third of participants in both groups had started conventional antidepressants, and the two groups were drawing closer together.
The trial's deepest difficulty was one the researchers could not design their way around: almost everyone knew which treatment they had received. Psilocybin produces an unmistakable altered state, and that knowledge is not neutral. Those who felt its effects may have carried amplified hope into their self-assessments; those who felt nothing may have carried quiet disappointment. Prior research suggests placebo groups in psilocybin trials tend to improve less than in conventional drug studies — a pattern that can make the drug appear more powerful than it may be on its own.
What the study adds, carefully, is evidence that psilocybin acts quickly and sustains its effects for months, even in people without treatment-resistant depression. What it cannot yet answer is the question that will define the field going forward: how much of the benefit belongs to the molecule, and how much to the meaning, expectation, and human care that inevitably travel with it.
Thirty-five people with recurring depression walked into a clinical trial expecting either relief or nothing at all. What researchers at Karolinska Institutet found was something in between those poles—and more complicated than either outcome alone.
The study, published in JAMA Network Open, gave half the participants a single dose of psilocybin while the other half received vitamin B3, a placebo designed to mimic some of the drug's physical sensations, like temporary flushing of the skin. Everyone received psychological support before, during, and after their assigned treatment. The researchers wanted to test whether psilocybin could help people with ordinary depression, not just those whose symptoms had resisted every other medication on the market.
By day eight, the difference was visible. Those who took psilocybin reported noticeable shifts in their mood. Six weeks in, more than half of them no longer met the clinical criteria for depression. In the placebo group, only one person improved to that degree. The drug was tolerated reasonably well, though two participants developed anxiety that persisted for several weeks.
But here is where the story becomes harder to read. The researchers followed everyone for a full year, watching to see how long the benefits would hold. The psilocybin group's gains lasted just over three months before beginning to fade. The placebo group, meanwhile, started improving on its own schedule—a pattern the researchers note is not unusual. Depression often moves in waves. Time and attention, even without an active drug, can ease symptoms.
About a third of participants in both groups eventually started antidepressant medication, typically around four months into the trial. The two groups were converging.
The central problem haunting this research is one of perception. Almost every participant figured out whether they had received psilocybin or placebo, despite the researchers' efforts to keep them blind. The drug produces an unmistakable altered state. You know when you have taken it. That knowledge matters. For those who felt psilocybin's effects, hope may have been amplified. For those who felt nothing, disappointment may have set in. Neither response is neutral when people later describe how they feel.
Previous research suggests that placebo groups in psilocybin trials improve less than placebo groups in traditional antidepressant studies. The researchers saw this pattern too. If the placebo group underperforms in the expected way, the gap between drug and placebo widens—making psilocybin look more powerful than it may actually be.
The findings do add to a growing body of evidence that psilocybin works quickly and holds its effects for months, even for people with ordinary depression rather than the severe, treatment-resistant kind. Those qualities could matter for patients. But the researchers are careful to name the thing they cannot yet untangle: how much of psilocybin's benefit comes from the drug itself, and how much comes from the experience of taking it, the expectation it carries, and the care that surrounds it. That question will shape how the field moves forward.
Citas Notables
Depression often comes in waves, and symptoms can ease over time without treatment.— Study authors, Hampus Yngwe and Johan Lundberg
How to disentangle the drug's biological effects from the powerful role of expectation and experience will be crucial for understanding where psilocybin fits into future mental health care.— Study authors, Hampus Yngwe and Johan Lundberg
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter whether people knew which treatment they received?
Because expectation shapes how we feel and how we report feeling. If you believe you've taken something powerful, that belief itself can ease your symptoms. The researchers can't separate the drug's chemistry from the psychology of receiving it.
So the placebo group's poor performance might be partly because they knew they didn't get the real thing?
Exactly. They felt nothing on dosing day, which likely confirmed their suspicion they'd drawn the placebo. That disappointment could have suppressed any natural improvement they might have experienced.
But psilocybin still worked better than placebo, right?
Yes, but the gap might be smaller than the numbers suggest. The real effect is probably somewhere between what the study shows and what a perfectly blinded trial would show.
What about the people who got better after three months? Did the drug stop working, or did depression just come back naturally?
The researchers can't say for certain. Depression cycles. Some of those people may have relapsed, others may have simply returned to baseline. The placebo group was improving by then too.
So what's the practical takeaway for someone considering this treatment?
Psilocybin appears to offer fast relief—within days—and that relief lasts for months. But you need psychological support alongside it, and you need realistic expectations about what happens after those three months end.